Nouvelle perspective de traitement pour le cancer de la vessie

La signature d’un contrat de license exclusive entre le CHUV et Prokarium, négocié par le PACTT, permettra le développement en partenariat d’un nouveau traitement découvert au Service d’urologie.

L’Unité de recherche du Service d’Urologie du CHUV, dirigée par la Dre Denise Nardelli-Haefliger et le Dr Laurent Derré, a développé un nouveau traitement du cancer de la vessie non-musculo invasif (NMIBC en anglais) basé sur l’immunothérapie. Cette thérapie consiste à utiliser un vaccin Salmonella administré par voie intravésicale dans le but de stimuler la réponse immunitaire contre la tumeur. (Pour plus de détails, voir les publications annexées). Dans le Service d’urologie du CHUV, sous la responsabilité du Prof. Patrice Jichlinski, du Prof Beat Roth et de la Dre Ilaria Lucca, le vaccin Salmonella Ty21a a fait l’objet d’un premier essai clinique de phase I qui a démontré un bon profil de sécurité à la dose sélectionnée. (Consulter le portail de l’Office fédéral de la santé publique (OFSP) consacré à la recherche sur l’être humain en Suisse).

La valorisation de cette recherche pour le bénéfice des patients, a débuté par le dépôt d’un brevet par le PACTT, qui a accompagné les inventeurs (Dr D. Nardelli-Haefliger, Prof P. Jichlinski and Dr. S. Domingos Pereira) tout au long du processus vers la commercialisation.

La signature de cet accord de licence entre le CHUV et Prokarium, compagnie de biotechnologie britannique pionnière dans l’immunothérapie microbienne, accorde des droits exclusifs d’exploiter commercialement le brevet détenu par le CHUV. Cette licence constitue une étape clé vers le développement de ce traitement innovant.

Lire le communiqué de presse de Prokarium.

Le cancer non-musculo invasif de la vessie touche chaque année 500’000 nouveaux patients dans le monde et représente 5% de tous les nouveaux cas de cancer. Au vu des nombreuses ruptures de stock du traitement de référence, le vaccin Bacillus Calmette-Guérin (BCG), ce dernier n’est pas toujours disponible pour tous les patients. Les chercheurs du service d’Urologie, se réjouissent de poursuivre et développer la recherche et les études de ce nouveau traitement Salmonella du cancer de la vessie.

 

Publications :

Abstract journal for immunotherapy of cancer

Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer

Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.

 

Back to news list

Sulfiscon awarded Innosuisse financing for its breakthrough treatment of osteoarthrisis

PACTT is proud to announce that Sulfiscon SA, a CHUV’s spin-off, led by the Dr. Alexander So, has received an Innosuisse financing to further the development of its innovative technology for the treatment of osteoarthritis, the most common degenerative disorder of the joints that affects more than half the elderly population worldwide. The project will be conducted in conjunction with Dr. Rainer Riedl from the Zurich University of Applied Sciences (ZHAW) and Dr. Sonia Nasi from the CHUV.

Dr. So and its Sulfiscon’s team were previously awarded in fall 2014 a FIT InnoTREK PACTT grant so as to complete an initial development phase of their technology tackling the root cause of osteoarthritis, a revolutionary approach to treat rather than only alleviate the pain as it is the case still today.

 

Back to news list

Imagine IF! 2022 – call for applications

Innovation Forum Lausanne, an association located at EPFL that is a branch of the global Innovation Forum network, is organizing the global accelerator event IMAGINE IF! for early-stage startups in the life science and cleantech field. The selected startups will be provided with networking opportunities, workshops and 1-1 mentoring with industry professionals. Most importantly, the winning venture of the first, local phase will take part in the second, global phase of the accelerator with access to a large network of industry professionals and entrepreneurs and gets the opportunity to pitch to international investors.

Application deadline : March 9, 2022

For more information : Accelerator | Innovation Forum (inno-forum.org)

Back to news list

InnoPACTT: a financial support to create your start-up

Spring CALL 2022

You are a UNIL-CHUV researcher who would like to create a start-up and need a financial support to start?

Apply for a one-year InnoTREK grant of CHF 100’000.- to launch your project!

PACTT, the Technology Transfer Office of UNIL-CHUV, is calling for start-up projects in order to award the InnoTREK grant. As part of the InnoPACTT financial support, the InnoTREK grant is designed to accelerate innovation and UNIL-CHUV spin-off creation, and to encourage researchers with innovative ideas to jump into the entrepreneurship adventure.

Deadline for submission: March 28, 2022

For conditions, registration form and information: www.pactt.ch/innotrek/

Contact: innopactt.info@chuv.ch

021 314 39 84 / 021 314 82 19

 

 

Back to news list

Venture Leaders Medtech Roadshow 2022

Venture Leaders Medtech brings 10 innovative Swiss startups to Boston from June 19th to June 23rd, 2022 for a week of intensive networking, business development and investor pitching. This will be an exclusive opportunity to get to know investors and international industry experts as a member of the “Swiss National Startup team”.

Until March 13th, 2022 startups will be able to apply for one of the 10 highly coveted slots. The program (worth about 10.000CHF) is organized by Venturelab and supported by EPFL, ETH, Hansjörg Wyss, Kellerhals Carrad, Paul Scherrer Insitut, Swissnex, Canton de Vaud and Canton Zürich, facilitating the participation free of charge for the startups.

Registration

Flyer

Back to news list

Venture Leaders Technology Roadshow 2022

Venture Leaders Technology brings 10 innovative Swiss startups to the Silicon Valley from April 3rd to April 9th, 2022 for a week of intensive networking, business development and investor pitching. This will be an exclusive opportunity to get to know investors and international industry experts as a member of the “Swiss National Startup team”.

Until January 16th, 2022 startups will be able to apply for one of the 10 highly coveted slots. The program (worth about 10.000CHF) is organized by Venturelab and supported by EPFL, ETH, DPD, Intel, Kellerhals Carrard, Rothschild & Co and Canton Vaud, facilitating the participation free of charge for the startups.

Registration

Flyer

Back to news list